Fundraising Fox
/Companies
Sign in

Dynavax

Unicorn exit · $2.2Bacquired by Sanofi

Düsseldorf, DE · 258 employees on LinkedIn · 3 known investors

Find your way into Dynavax

Each arrow is one introduction. Sign up to fill in the first one.

924 people can intro you to Andrew

Ask Laizer Kornwasser to introduce you to Andrew Davis

You →Laizer · together at Bausch Health Companies Inc. →Andrew

225 people can intro you to Donn

Ask Jamie Chen to introduce you to Donn Casale

You →Jamie · together at ARS Pharmaceuticals →Donn

Sign up to find every way you can get introduced to Dynavax

  • Your email: who you already know at Dynavax, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Dynavax team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

Acquired by Sanofi December 2025 · $2.2B ($15.50 per share cash, ~$2.2 billion total equity value) · source ↗

Dynavax is a commercial-stage biopharmaceutical company that develops and commercializes vaccines against infectious diseases using its adjuvant technology. Its products target immunization and infectious disease prevention.

BiotechHealthtech

Founders & leadership

RSRyan Spencer
Ryan SpencerChief Executive OfficerChief Executive Officer at Dynavax NASDAQ: DVAX www.dynavax.com
DNDavid Novack
David NovackPresident and Chief Operating OfficerPresident and Chief Operating Officer at Dynavax NASDAQ: DVAX www.dynavax.com
RJRobert Janssen
Robert JanssenChief Medical Officer and Senior Vice President, Clinical DevelopmentChief Medical Officer and Senior Vice President, Clinical Development at Dynavax NASDAQ: DVAX www.dynavax.com
KMKelly MacDonald
Kelly MacDonaldChief Financial OfficerChief Financial Officer at Dynavax NASDAQ: DVAX www.dynavax.com
JCJeff Coon
Jeff CoonChief Human Resources Officer
DCDonn Casale
Donn CasaleChief Commercial OfficerCasale is Chief Commercial Officer at Dynavax, a biopharmaceutical company developing vaccines using adjuvant technology. He has over 25 years of experience in biopharmaceutical commercial leadership, including scaling the company's U.S. commercial platform and growing HEPLISAV-B revenue from $62M in 2021 to over $300M annualized by 2025, and has led commercial strategy across vaccines, infectious disease, pain, and neurology across various roles.
ADAndrew Davis
Andrew DavisChief Business OfficerAndrew Davis is Chief Business Officer at Dynavax, a vaccine company using adjuvant technology for infectious disease prevention. He brings extensive experience in corporate development and strategy, including numerous mergers, acquisitions, licensing deals, and partnerships across multiple therapeutic areas including dermatology, ophthalmology, and oncology.

Investors · 3

HealthCaplisted by HealthCapStockholm

How we know: HealthCap's portfolio page · Not right? Tell us

Sanderling Ventureslisted by Sanderling VenturesSan Mateo · $50K – $1M

How we know: Sanderling Ventures's portfolio page · Not right? Tell us

Founder mafia

2 people who came through Dynavax went on to found or lead other companies.

Julie EastlandBoard Member / Audit Committe ChairFounded Harpoon Therapeutics +1Donn CasaleChief Commercial OfficerFounded ARS Pharmaceuticals

Related companies · 1

MedscapeMedscape is an online platform providing medical news, clinical information, and continuing education resources to physicians and healthcare professionals globally. The platform offers CME courses, drug and disease information, and patient education across multiple specialties.

Companies working in the same space as Dynavax.

Non-dilutive funding · 11 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase II2016$1M
National Institutes of Health (NIH)National Institutes of HealthPhase ISTTR2013$223.4K
National Institutes of Health (NIH)National Institutes of HealthPhase I2012$599K
National Institutes of Health (NIH)National Institutes of HealthPhase I2012$404.9K
National Institutes of Health (NIH)National Institutes of HealthPhase I2011$595.5K
National Institutes of Health (NIH)National Institutes of HealthPhase I2010$595.8K
National Institutes of Health (NIH)National Institutes of HealthPhase I2009$720.3K
National Institutes of Health (NIH)National Institutes of HealthPhase II2008$1.8M
National Institutes of Health (NIH)National Institutes of HealthPhase I2006$207.3K
National Institutes of Health (NIH)National Institutes of HealthPhase I2002$119.3K
National Institutes of Health (NIH)National Institutes of HealthPhase I2000$100K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

What does Dynavax do?
Dynavax is a commercial-stage biopharmaceutical company that develops and commercializes vaccines against infectious diseases using its adjuvant technology. Its products target immunization and infectious disease prevention.
Who are Dynavax's investors?
Dynavax's investors include Bain Capital Life Sciences, HealthCap, Sanderling Ventures.
Who acquired Dynavax?
Dynavax was acquired by Sanofi.
Where is Dynavax headquartered?
Dynavax is headquartered in Düsseldorf, DE.